A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD)

计划入组 100 人 · 首次发布于 2014 年 9 月 18 日

Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma

计划入组 120 人 · 首次发布于 2017 年 5 月 8 日

NIOX VERO Nasal Application in Primary Ciliary Dyskinesia

计划入组 163 人 · 首次发布于 2015 年 12 月 4 日

PCD-04

PCDH19

PCD gene 3 Targeting Primary ciliary dyskinesia Program(ReCode Therapeutics, Inc.)

PKD Foundation

United States

Pci Biotech As

Sweden

PDC Biotech GmbH

Austria

ReCode Therapeutics Achieves First Clinical Proof of mRNA Therapy Activity in Primary Ciliary Dyskinesia

University of Iowa Researchers Secure Nearly $12 Million NIH Grant to Develop Gene Editing Treatments for Primary Ciliary Dyskinesia

Ethris's Inhaled mRNA Therapy Shows Promise in Phase 1 Asthma Trial